

Reference:	FOI.20914.26
Subject:	Diffuse Large B Cell Lymphoma (DLBCL)
Date of Request:	2 July 2026

Requested:

- 1a. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
- 1b. Of these patients, how many commenced treatment at your trust within the last 6 months?
2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
 - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
 - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
 - Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
 - R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
 - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
 - R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
 - (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
 - R-GemOX (rituximab, gemcitabine and oxaliplatin)
 - Axicabtagene ciloleucel
 - Tisagenlecleucel
 - Epcoritamab
 - Loncastuximab tesirine
 - Glofitamab
 - Any other SACT
 - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
 - Glofitamab + GemOx (gemcitabine and oxaliplatin)

Response:

Hywel Dda University Health Board (UHB) regrets to inform you that it does not hold the information requested for the following treatments: R-CODOX-M, R-IVAC, (DA)-EPOCH +/-R, Axicabtagene ciloleucel, Tisagenlecleucel or Stem cell/bone marrow transplant. The UHB's patients requiring these treatments are seen, treated and managed by either Swansea Bay University Health Board (SBUHB) or Cardiff and Vale University Health Board (C&VUHB). Therefore, we recommend that you redirect these parts of your request to the Freedom of Information Team (FoI) at SBUHB and C&VUHB, who may be able to help you further.

Treatments for R-CODOX-M, R-IVAC and (DA)-EPOCH +/-R are managed by SBUHB, who are contactable at:

- FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.

Treatments for Axicabtagene ciloleucel, Tisagenlecleucel and Stem cell/bone marrow transplant are managed by C&VUHB, who are contactable at:

- FOI.Requests@wales.nhs.uk or alternatively, you can contact: Freedom of Information, Cardiff and Vale University Health Board, University Hospital for Wales, Health Park, Cardiff, CF14 4XW.

1a. The UHB confirms that thirty-three (33) patients were diagnosed with DLBCL, during the period 1 January to 30 June 2026.

1b. Of those identified in response to question 1a, thirty-one (31) patients commenced treatment within the UHB, during the period 1 January to 30 June 2026.

2b. The UHB provides within the table below, the number of DLBCL patients that have received the treatments listed, as recorded on the ChemoCare system, during the period 1 January to 30 June 2026.

Medication	Number
R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	8
R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	10
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	0
Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)	11
R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)	Not held
R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)	Not held
R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)	*
(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)	Not held
R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
Axicabtagene ciloleucel	Not held
Tisagenlecleucel	Not held
Epcoritamab	0
Loncastuximab tesirine	0
Glofitamab	0
Any other SACT	*
Stem cell transplant or bone marrow transplant (autologous or allogeneic)	Not held
Glofitamab + GemOx (gemcitabine and oxaliplatin)	*